In this role, Dr. Evenbratt will be responsible for the overall leadership of the Company's research, product development and production efforts. This includes directing the development of Cline's preclinical projects (StemCART and CellRACE) into the next phases. Prior to this appointment, Dr. Evenbratt served as Director of Product Development, and she has been an integral part of the company since 2014. Dr. Evenbratt initiated the work that has evolved to Cline's cell-based joint therapy project, StemCART, from inception to the exciting stage it is today.

Before joining Cline, Dr. Evenbratt's previous experience includes conducting research within the Department of Dermatology at Sahlgrenska University Hospital, as well as at AstraZeneca where she explored polymer analysis and GMP production. Dr. Evenbratt holds a Ph.D. degree in Pharmaceutical Technology from Chalmers University of Technology. Her thesis included leading nanotechnology-based projects, research cooperations between different departments within Chalmers and Gothenburg University, as well as at Stanford University and the University of Texas. 

"Dr. Evenbratt has played a vital role in the development of Cline Scientific from a start-up venture to the Life Science R&D company it is today. Both her knowledge as well as her skilled handling of the sensitive and challenging processes in the infancy of a Life Science venture has been, and is, extraordinary. In addition, as the saying goes, "she comes to play everyday", without a doubt the most important and sought-after characteristic a team member can have. We are impressed by her efforts, and therefore it gives us great pleasure to promote her into a position where we know she will excel!" Patrik Sundh, CEO

For more information, please contact:
Patrik Sundh, CEO
Email: patrik.sundh@clinescientific.com 
Phone: +46 0703585088